What Physicians Should Ask
Any Peptide Supplier
Before Signing

The compounded GLP-1 peptide market expanded faster than quality controls could follow. Between 2022 and 2025, hundreds of suppliers entered the space with varying levels of rigor, some operating under rigorous pharmaceutical standards, others cutting corners that are not visible to the prescribing physician until something goes wrong.

Before you commit to any supplier — including Majestic — you should be able to get clear, direct answers to each of the following seven questions. If a supplier hedges, deflects, or cannot answer any of them, that is your answer.

Question 1: Where are your compounds manufactured?

The answer should be a specific facility name and location. If the supplier cannot tell you exactly where their compounds are manufactured and by whom, they either do not know or they do not want you to know. Both are problems.

The distinction that matters is between a supplier who manufactures domestically and one who sources API (active pharmaceutical ingredient) overseas and repackages it domestically. These are not the same thing. Ask explicitly: "Is this compound synthesized in the US, or is the API imported and then processed here?"

Question 2: Is your manufacturing facility USP-797 certified?

USP Chapter <797> is the federal compendial standard for sterile compounded preparations, meaning any compounded product intended for injection. A facility that is not USP-797 compliant is not operating to the standard required for compounded injectables under federal guidelines.

Question 3: Can I see the Certificate of Analysis for a current lot?

A Certificate of Analysis (COA) is a document from a testing laboratory that confirms the identity, purity, and quantity of a specific compound lot. Every legitimate compounded peptide should ship with a COA from an independent third-party laboratory, not from the supplier's in-house testing.

The key word is independent. A COA issued by the same entity selling you the product is not independent verification. Ask specifically: "Which third-party laboratory tests your lots, and can I verify the COA directly at that laboratory's portal?"

Question 4: Can I visit the facility?

This question is a filter, not a requirement. The answer tells you everything about the supplier's confidence in their operation. A facility that welcomes visits is a facility that has nothing to hide. A supplier that deflects, delays, or makes visits "very difficult to arrange" is signaling something.

You do not have to visit, but the offer should be genuine and straightforward. If you are putting $30,000 of inventory into your practice and your name on the prescription, you are entitled to see where the compound was made.

Question 5: What are the full terms of your financing or payment structure?

Some suppliers require large upfront inventory purchases without any financing pathway, creating a capital barrier that limits access to established practices. Others offer financing arrangements where the terms may not be as favorable as presented, variable rates, prepayment penalties, or personal credit requirements buried in the fine print.

Ask for the complete written terms before signing anything. Specifically: fixed vs. variable rate, term length, monthly payment amount, prepayment penalty, collateral requirements, and personal vs. business credit check. If any of these cannot be answered clearly in writing, that is a red flag.

Question 6: What clinical training and onboarding support is included?

A compound is only as safe as the protocol governing its use. A supplier who sells you peptides without offering structured clinical training, on mechanism of action, candidate selection, contraindications, reconstitution, storage, and adverse event monitoring, is selling you a product, not a turn-key program.

Ask what is specifically included: Who delivers the training? How many hours? Is it remote or in-person? Are recordings and protocol documents provided? Is ongoing support available after launch?

Question 7: What compliance documentation do you provide?

Running a compliant compounded peptide program requires documentation that most physicians do not have sitting in their EMR: informed consent templates specific to each compound, adverse event reporting forms, lot tracking logs, reconstitution and storage cards, and EMR documentation guidance. Building this from scratch is time-consuming and introduces risk.

A serious program provides these materials as part of onboarding — not as an add-on or afterthought. Ask to see examples of the documentation templates before committing.

The bottom line

You are a licensed practitioner. The compounds you prescribe carry your name, your DEA number, and your professional liability. The seven questions above are the minimum standard. Any supplier unwilling or unable to answer them clearly is not operating at the standard your patients deserve.

At Majestic, we welcome that conversation, and we welcome the scrutiny. If you want to run through them with us directly, the contact information below is the right place to start.